Cargando…
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
BACKGROUND: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. METHODS: Measures included adverse events (AE), clinical Disease Activity Index for Psoriatic Arthritis (...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251537/ https://www.ncbi.nlm.nih.gov/pubmed/37296456 http://dx.doi.org/10.1186/s13075-023-03078-8 |
_version_ | 1785055968311115776 |
---|---|
author | Gossec, Laure Theander, Elke Chakravarty, Soumya D. Bergmans, Paul Lavie, Frederic Noël, Wim Sharaf, Mohamed Siebert, Stefan Smolen, Josef S. |
author_facet | Gossec, Laure Theander, Elke Chakravarty, Soumya D. Bergmans, Paul Lavie, Frederic Noël, Wim Sharaf, Mohamed Siebert, Stefan Smolen, Josef S. |
author_sort | Gossec, Laure |
collection | PubMed |
description | BACKGROUND: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. METHODS: Measures included adverse events (AE), clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) low disease activity (LDA) including remission, Psoriatic Arthritis Impact of Disease-12 (PsAID-12), Minimal Disease Activity, dactylitis, nail/skin involvement and time to treatment stop. Data were analysed descriptively. RESULTS: Overall, 336 patients < 60 and 103 ≥ 60 years received ustekinumab, with a similar gender balance. A numerically lower proportion of younger patients reported at least one AE: 124/379 (32.7%) vs 47/115 (40.9%) for patients < 60 and ≥ 60 years, respectively. Serious AEs were low (< 10%) in both groups. At 6 months, the proportion of patients with cDAPSA LDA was 138/267 (51.7%) and 35/80 (43.8%) for patients < 60 and ≥ 60 years, respectively, with the effectiveness being maintained through 36 months. PsAID-12 mean scores reduced for both groups from a baseline mean of 5.73 and 5.61 for patients < 60 and ≥ 60 years, respectively, to 3.81 and 3.88, respectively, at 6 months, and 2.02 and 3.24, respectively, at 36 months. Regarding treatment persistence, 173/336 (51.5%) vs 47/103 (45.6%) patients < 60 and ≥ 60 years, respectively, stopped or switched treatment. CONCLUSION: Fewer AEs were observed over 3 years for younger versus older patients with PsA. There were no clinically meaningful treatment response differences. Persistence was numerically higher in the older age group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03078-8. |
format | Online Article Text |
id | pubmed-10251537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102515372023-06-10 Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study Gossec, Laure Theander, Elke Chakravarty, Soumya D. Bergmans, Paul Lavie, Frederic Noël, Wim Sharaf, Mohamed Siebert, Stefan Smolen, Josef S. Arthritis Res Ther Research BACKGROUND: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. METHODS: Measures included adverse events (AE), clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) low disease activity (LDA) including remission, Psoriatic Arthritis Impact of Disease-12 (PsAID-12), Minimal Disease Activity, dactylitis, nail/skin involvement and time to treatment stop. Data were analysed descriptively. RESULTS: Overall, 336 patients < 60 and 103 ≥ 60 years received ustekinumab, with a similar gender balance. A numerically lower proportion of younger patients reported at least one AE: 124/379 (32.7%) vs 47/115 (40.9%) for patients < 60 and ≥ 60 years, respectively. Serious AEs were low (< 10%) in both groups. At 6 months, the proportion of patients with cDAPSA LDA was 138/267 (51.7%) and 35/80 (43.8%) for patients < 60 and ≥ 60 years, respectively, with the effectiveness being maintained through 36 months. PsAID-12 mean scores reduced for both groups from a baseline mean of 5.73 and 5.61 for patients < 60 and ≥ 60 years, respectively, to 3.81 and 3.88, respectively, at 6 months, and 2.02 and 3.24, respectively, at 36 months. Regarding treatment persistence, 173/336 (51.5%) vs 47/103 (45.6%) patients < 60 and ≥ 60 years, respectively, stopped or switched treatment. CONCLUSION: Fewer AEs were observed over 3 years for younger versus older patients with PsA. There were no clinically meaningful treatment response differences. Persistence was numerically higher in the older age group. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03078-8. BioMed Central 2023-06-09 2023 /pmc/articles/PMC10251537/ /pubmed/37296456 http://dx.doi.org/10.1186/s13075-023-03078-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Gossec, Laure Theander, Elke Chakravarty, Soumya D. Bergmans, Paul Lavie, Frederic Noël, Wim Sharaf, Mohamed Siebert, Stefan Smolen, Josef S. Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title_full | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title_fullStr | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title_full_unstemmed | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title_short | Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study |
title_sort | response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the psabio real-world study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251537/ https://www.ncbi.nlm.nih.gov/pubmed/37296456 http://dx.doi.org/10.1186/s13075-023-03078-8 |
work_keys_str_mv | AT gosseclaure responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT theanderelke responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT chakravartysoumyad responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT bergmanspaul responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT laviefrederic responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT noelwim responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT sharafmohamed responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT siebertstefan responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy AT smolenjosefs responsetotreatmentinpsoriaticarthritistheeffectofageanalysisofpatientsreceivingustekinumabinthepsabiorealworldstudy |